AstraZeneca Aktie
WKN: 886715 / ISIN: US0463531089
24.10.2023 13:33:43
|
AstraZeneca : FDA Accepts For Review SBLA For Self-administration Of Flumist Quadrivalent
(RTTNews) - AstraZeneca PLC (AZN.L, AZN) said that its Supplemental Biologics License Application or sBLA for the approval of a self- or caregiver-administered option for Flumist Quadrivalent (Influenza Vaccine Live, Intranasal), a needle-free nasal spray, has been accepted for review by the US Food and Drug Administration.
If approved, Flumist Quadrivalent will be the first flu vaccine available to be self-administered by eligible patients or administered by caregivers, adding an additional option to be vaccinated against influenza.
The company noted that the sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer or administer Flumist Quadrivalent to eligible patients 2-49 years of age when given instructions for use without any additional guidance. Flumist Quadrivalent, which is sprayed into the nose, has extensive data demonstrating comparable effectiveness and acceptable safety relative to other flu vaccines.
The Prescription Drug User Fee Act (PDUFA) date, the FDA's date for a regulatory decision, is expected during the first quarter of 2024. If approved at that time, Flumist Quadrivalent is anticipated to be available for self-administration in the US for the 2024/2025 flu season.
For More Such Health News, visit rttnews.com

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AstraZeneca PLC (spons. ADRs)mehr Nachrichten
23.07.25 |
Gewinne in New York: Börsianer lassen NASDAQ 100 steigen (finanzen.at) | |
22.07.25 |
AstraZeneca-Aktie höher: AstraZeneca stärkt US-Präsenz mit Milliarden-Investitionsprogramm (Dow Jones) | |
17.07.25 |
Aufschläge in New York: Gewinne im NASDAQ 100 (finanzen.at) | |
17.07.25 |
Aufschläge in New York: NASDAQ 100 zeigt sich am Mittag fester (finanzen.at) | |
16.07.25 |
AstraZeneca-Aktie im Minus: Anselamimab hat Studienziel nicht erreicht (Dow Jones) | |
14.07.25 |
Erste Schätzungen: AstraZeneca gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) | |
04.07.25 |
AstraZeneca-Aktie höher: Summit Therapeutics und AstraZeneca sprechen über Ivonescimab-Deal (Dow Jones) | |
03.07.25 |
NASDAQ-Handel: NASDAQ 100 verbucht zum Handelsende Gewinne (finanzen.at) |
Analysen zu AstraZeneca PLC (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 62,50 | 1,63% |
|